Linezolid was developed by Pfizer Pharmacia and was approved by the U.S. FDA on April 18, 2000. Linezolid tablets are a relatively powerful antibacterial drug used to treat the following infections caused by sensitive microorganisms. Sexual diseases: hospital-acquired pneumonia caused by Staphylococcus aureus (methicillin-sensitive and resistant strain) or Streptococcus pneumoniae. Community-acquired pneumonia caused by Streptococcus pneumoniae, including concomitant bacteremia, or community-acquired pneumonia caused by Staphylococcus aureus (only a methicillin-sensitive strain). Including diabetic foot infections without osteomyelitis, complicated skin and skin soft tissue infections caused by Staphylococcus aureus (methicillin-sensitive and resistant strains), Streptococcus pyogenes or Streptococcus agalactiae. There is no research on the use of linezolid in the treatment of bedsores. Uncomplicated skin and skin soft tissue infections caused by Staphylococcus aureus (only methicillin-sensitive strains) or Streptococcus pyogenes.
Linezolid Industry Status Analysis and Prospect Forecast
Linezolid is a bacterial protein synthesis inhibitor. Unlike other drugs, linezolid does not affect the activity of peptidyl transferase. It only acts on the initial stage of the translation system, inhibits the connection of mRNA and ribosomes, and prevents the 70S initiation complex. Formed, thereby inhibiting the synthesis of bacterial protein. Linezolid has a special location and mode of action. Therefore, in positive bacteria with essential or acquired resistance characteristics, it is not easy to cross-resistance with other antibacterial drugs that inhibit protein synthesis. It is not easy to induce bacterial resistance in vitro. Genes that produce resistance to antibacterial drugs acting on the 50S ribosomal subunit are not effective for linezolid. At present, the market mainly includes linezolid injection and linezolid tablets. As of 2019, linezolid injection accounted for 73.29% of the market share, ranking first; linezolid tablets accounted for 26.71% of the market share.
Staphylococcus aureus usually inhabits the skin or nasal cavity, and its transmission is almost always caused by direct or indirect contact with infected patients, mainly involving pneumonia, skin and skin and soft tissue infections, bloodstream infections, and bone infections. Methicillin-resistant golden grapes are widely prevalent in the world. In recent years, the proportion of methicillin-resistant golden grapes has been increasing globally, especially in the elderly and critically ill patients. After years of application and feedback in the patient market, the clinical treatment effect of linezolid tablets is particularly good. It can significantly increase the sputum conversion rate of tuberculosis patients, alleviate the suffering of patients, and improve their survival rate. However, the price is extremely expensive. The price of one piece of genuine svolinezolid produced by Pfizer Pharmaceuticals Co., Ltd. is as high as 450 yuan, and patients need to take one piece a day. The cost of the drug for a month is as high as 13,000 yuan. The treatment of drug-resistant tuberculosis is a long-term continuous process. . Although the price of Indian linezolid, which is woven by an Indian pharmaceutical company, will be much lower, its effect cannot be guaranteed. As of 2019, the global linezolid industry market value was USD 32 million. In the future, as the world enters an age of aging, the market value of the linezolid industry is expected to continue to rise.
After invading the human body, tuberculosis bacilli often do not immediately show related clinical symptoms, but after a period of incubation, tuberculosis can be caused when the patient's immune system declines. The recurrence rate of the disease is high, and the retreatment effect is not good, and it can easily become an important persistent source of infection of tuberculosis. Mycobacterium tuberculosis has high drug resistance, which may make patients resistant to anti-tuberculosis drugs, which in turn increases the difficulty of clinical treatment. However, the clinical treatment effect of linezolid tablets is particularly good, and it is not easy to induce bacterial resistance in vitro. With the widespread use of linezolid at home and abroad, affected by its selling price, in the current market, there are many different versions, generally divided into imitation version and genuine version. The genuine version includes the European English version and the Chinese Swan version; generic drugs mainly refer to the Indian version. However, since July 2020, Chongqing Huabang Pharmaceutical Co., Ltd. has been approved by the National Medical Products Administration to produce generic linezolid tablets.This product has become the first generic drug for linezolid tablets in China. The emergence of this batch of textile drugs once again brought a huge price shock to the linezolid market, and also brought good news to many drug-resistant tuberculosis patients in the future. The Asia-Pacific region may be affected by this, and market share is expected to continue to rise. As of 2019, North America’s market share is 25.71%; Europe’s market share is 21.91%; Asia Pacific’s market share is 43.30%.
The Impact of COVID-19 on the Linezolid Industry
Since the outbreak of COVID-19 in early 2020, the virus has spread to all parts of the world, spreading widely, and causing great harm to the global economy. During the epidemic, governments of various countries have introduced a series of measures such as extending holidays and delaying business operations. The flow of people reduces the occurrence of cross-infection, and many companies are unable to carry out normal production and operation. For the linezolid industry, the epidemic has led to a sharp drop in the passenger flow of offline pharmacies. Some companies that do not use online promotion methods for marketing have encountered great resistance to their development despite the disruption of the original offline market development plan. The impact is short-term, but it still loses a large number of customers and is on the verge of bankruptcy. But for pharmaceutical companies with developed e-commerce, they are less affected by the epidemic, and even rely on the outstanding performance of e-commerce to attract more customers during the epidemic. In the future, as economies around the world gradually recover, the linezolid industry will slowly return to normal. It is worth noting that the epidemic fluctuates repeatedly around the world. Although the industry gradually returns to normal, companies should continue to pay attention to online sales. The maintenance of the channel minimizes the harm caused by the epidemic to the industry repeatedly.
We provide more professional and intelligent market reports to complement your business decisions.
Chinese